Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Up - Still a Buy?

Key Points

• Bio-Rad Laboratories (NYSE:BIO.B) shares experienced a significant increase, opening at $283.85 after closing at $247.05.
• The company reported a quarterly earnings per share (EPS) of $2.61, with a net margin of 12.50% and a return on equity of 4.01%.
• Bio-Rad has a market capitalization of $7.75 billion and maintains a low debt-to-equity ratio of 0.17, indicating strong financial health.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $247.05, but opened at $283.85. Bio-Rad Laboratories shares last traded at $284.88, with a volume of 345 shares traded.

Bio-Rad Laboratories Stock Performance

The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12. The company has a market cap of $7.75 billion, a PE ratio of 24.29 and a beta of 0.78. The firm's 50 day moving average is $251.39 and its 200-day moving average is $248.42.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.61 EPS for the quarter. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.